Vaxcyte's Insider Exodus: Why CEO Sales Cloud a Bullish Biotech Narrative

Related Articles

Guidewire Software's Insider Exodus: Why Executive Sales Cloud a Bullish Outlook

3 months ago

MicroStrategy's Insider Exodus: Why Director Sales Undermine the Bitcoin Narrative

3 months ago

Adaptive Biotechnologies: Why Executive Sales Cloud a Biotech Growth Story

3 months ago

Fastly's Insider Exodus: Why CEO Sales Signal Caution Despite AI Hype

3 months ago

Category

You may also like

Stock News•2 weeks ago

Biotech's Rebound Reality: Surging M&A Deals Meet Deep Retail Skepticism

Biotech stocks are rebounding as pharma M&A hits record highs to counter patent cliffs, though retail investors remain skeptical.

ABBV

Share

Stock News•1 months ago

A Vaxcyte Executive Just Cashed Options Struck at $5.35. Here's What Long-Term Investors Should Know

Vaxcyte executive Jim Wassil cashed options struck at $5.35, realizing about $378,000 at $61.12 per share, equal to 4% of his prior stake. The sale may signal reduced insider conviction, though long-t...

PCVX

Share

Stock News•3 months ago

An Adaptive Biotechnologies Insider Sold $8.5 Million in Stock After an 85% Run

An Adaptive Biotechnologies insider sold ~386K shares for $8.5M on July 2, 2026, after the stock's 85% run-up.

ADPT

Share